Pharming hit by guidance cut and CEO exit, offset by Joenja label wins
Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.
The guidance cut is the single biggest negative force behind the stock's move this period.
Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.
It is a new negative overhang that can affect the stock beyond the one-day drop.
Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.
These approvals are the main positive counterweight to the weak RUCONEST story.
CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.
An abrupt CEO departure is a fresh governance risk that can hold the stock back.